1-Phenyl-4-isobutyl-piperazin | 21048-87-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-Phenyl-4-isobutyl-piperazin
• 英文别名: 1-isobutyl-4-phenyl-piperazine；1-(2-Methylpropyl)-4-phenylpiperazine
• CAS: 21048-87-3
• 化学式: C₁₄H₂₂N₂
• mdl: MFCD16310407
• 分子量: 218.342
• InChiKey: UMFDOOWMKLRAAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Phenyl-4-isobutyl-piperazin 、 chloroamine-T 、 disodium;dioxido-oxo-sulfanylidene-λ6-sulfane 生成 1-(4-(125I)iodanylphenyl)-4-(2-methylpropyl)piperazine
  参考文献：
  名称：

  HANSON R. N.; HASSAN M., J. MED. CHEM., 30,(1987) N 1, 29-34

  摘要：

  DOI：
• 作为产物：
  描述：

  N-苯基哌嗪 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 6.0h， 生成 1-Phenyl-4-isobutyl-piperazin
  参考文献：
  名称：

  N-烷基和N-芳基哌嗪衍生物的合成和抗菌活性。

  摘要：

  已经合成了一系列取代的哌嗪衍生物，并测试了其抗菌活性。测试了对金黄色葡萄球菌（MTCCB 737），铜绿假单胞菌（MTCCB 741），表皮链霉菌（MTCCB 1824）和大肠杆菌（MTCCB 1652）的抗菌活性，以及​​对烟曲霉，黑曲霉和黄曲霉的抗真菌活性。所有合成的化合物均显示出对细菌菌株的显着活性，但对被测真菌的活性较低。体外毒性试验表明，化合物4d和6a对人红细胞的毒性很小。

  DOI：

  10.1016/j.bmc.2005.10.032

文献信息

• NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20160168139A1

  公开（公告）日：2016-06-16

  There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z 2 represents CH or the like; Z 1 represents CR 6 or the like; R 6 represents a hydrogen atom or the like; X 1 represents CHR 7 or the like; R 7 represents a hydrogen atom or the like; X 2 represents CH 2 or the like; R 1 and R 2 are the same as or different from each other, and each of R 1 and R 2 represents a hydrogen atom or the like; R 3 , R 4 , and R 5 are the same as or different from each other, and each of R 3 , R 4 , and R 5 represents a hydrogen atom, NR a R b , or the like; and each of R a and R b represents a hydrogen atom, a C 1-8 alkyl group which may have a substituent, or the like.)

  提供一种由通用式[1A]表示的吗啉衍生物或其盐。 （在该式中，环A代表由通用式[I]表示的环；*代表连接位置；Z 2 代表CH或类似物；Z 1 代表CR 6 或类似物；R 6 代表氢原子或类似物；X 1 代表CHR 7 或类似物；R 7 代表氢原子或类似物；X 2 代表CH 2 或类似物；R 1 和R 2 相同或不同，且R 1 和R 2 中的每一个代表氢原子或类似物；R 3 ，R 4 和R 5 相同或不同，且R 3 ，R 4 和R 5 中的每一个代表氢原子，NR a R b 或类似物；R a 和R b 中的每一个代表氢原子，可能具有取代基的C 1-8 烷基基团，或类似物。）
• 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE
  申请人：Kubota Hideki

  公开号：US20080227785A1

  公开（公告）日：2008-09-18

  This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

  本发明涉及一种以BEC 1钾离子通道抑制剂作为活性成分的抗痴呆剂。已经证明，BEC 1钾离子通道抑制剂具有改善学习障碍的作用，并且作为预防或治疗剂是有用的，尤其是对于BEC 1钾离子通道与之相关的疾病，如痴呆症。例如，通过体内试验证实，BEC 1钾离子通道抑制剂具有改善学习障碍的作用。此外，还发现具有2,4,6-三氨基-1,3,5-三嗪的化合物具有BEC 1钾离子通道抑制作用。
• ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS
  申请人：Stenkamp Dirk

  公开号：US20090069282A1

  公开（公告）日：2009-03-12

  The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R 1 and R 2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的炔化合物，其中A、B、W、X、Y、Z、R1和R2的基团和残基具有权利要求1中给出的含义。本发明还涉及包含至少一种根据本发明的炔烃的制药组合物。鉴于它们的MCH受体拮抗活性，根据本发明的制药组合物适用于治疗代谢性疾病和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。
• HANSON R. N.; HASSAN M., J. MED. CHEM., 30,(1987) N 1, 29-34
  作者：HANSON R. N.、 HASSAN M.

  DOI：——

  日期：——
• SYNTHESIS OF METHYL NONACTATE DERIVATIVES
  申请人：Bergmeier Stephen C.

  公开号：US20100056779A1

  公开（公告）日：2010-03-04

  Methyl nonactate is converted into a variety of different triazoloamide antibacterial agents by a reaction scheme involving (1) inversion of the secondary alcohol of the methyl nonactate to produce the corresponding azidoester, (2) converting the azido ester to the corresponding azidoamide, and (3) converting the azido group of the azidoamide to a triazole to produce the corresponding triazoloamide.